ART Advanced Research Technologies http://www.art.ca/en/ en-ca Copyright 2007 daily ART Announces Completion of Restructuring Process with Implementation of Its Proposal Filed Under the Bankruptcy and Insolvency Act http://www.art.ca/en/news-events/press-release-art-announces-completion-restructuring-process-545.php?y=2009 Montreal, Canada, December 14, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company specializing in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that it has emerged from its Court-supervised restructuring on December 11, 2009.All transactions in connection with the implementation of the proposal filed by ART under the Bankruptcy and Insolvency Act (Canada) ("BIA") (the "Proposal") and the reorganization of ART's equity pursuant to Section 191 of the Canada Business Corporation Act (the "Reorganization") included therein have been completed.ART's President, Sébastien Gignac, stated: "With Dorsky Worldwide Corp.'s critical support and the closing of the Proposal, ART is able to emerge from this restructuring process with the perspective of pursuing within a new group its operations and maintaining its highly-skilled and dedicated workforce as well as supporting its valuable clients. We wish to extend our deepest gratitude to our suppliers, service providers and distributors, for the strong support which they have given us throughout this difficult process. We intend to pursue the growth of our relationship with them to build a bright future together. It is regretful that our shareholders who have shared ART's history for many years until the very end have not realized value and have been disappointed by their investment in the ART. They have nonetheless participated in the development of a unique imaging platform and of two great molecular imaging products, SoftScan® and Optix®, whose true value will be to improve people's lives, especially women's, and get new and better drugs to market quicker. ART's challenging restructuring enables the survival of a reliable and state of the art technology emanating from Québec, Canada, in particular in the areas of cancer diagnostic and treatment monitoring, which are generating growing debates and high expectations unmet by conventional modalities", concluded Mr. Gignac. ART obtained creditors approval of the Proposal on December 7, 2009 and a final order of the Quebec Superior Court of Justice (the "Court") under the BIA on December 9, 2009. Pursuant to the Proposal, Dorsky Worldwide Corp. ("Dorsky") has settled the claims of secured creditors of ART totaling close to $5 million and funded a distribution of $375,000 to be made by the Court-appointed trustee to the unsecured creditors of ART.  Dorsky is now ART's sole shareholder.All existing common and preferred shares and other equity of ART outstanding prior to the implementation of the Proposal have been automatically cancelled, without payment or compensation to the holders of such shares and equity, in accordance with the terms of the Court approved Proposal. All warrants, rights, options, agreements and instruments to purchase shares of ART existing prior to the Proposal implementation are of no further force or effect, in accordance with the terms of the Court approved Proposal.The common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of ART were de-listed from the Toronto Stock Exchange ("TSX") at the close of business on December 11, 2009. ART will apply to cease to be a reporting issuer in all applicable Provinces and territories of Canada.About ART ART Advanced Research Technologies Inc. develops and commercializes molecular imaging products for the healthcare and pharmaceutical industries. In accordance with TSX Bulletin No.2 009-1426 dated November 3, 2009, the TSX determined on November 12, 2009 to delist the common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of the Company (collectively, the "Securities") at the close of market on December 11, 2009 for failure to meet the continued listing requirements of TSX. For more information on ART and its restructuring, visit our website at www.art.ca.FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Sébastien Gignac:  sgignac@art.caPresident and Chief Executive OfficerTel.  514.832.0777Jacques Bédard:  jbedard@art.ca Chief Financial OfficerTel.  514.832.0777www.art.ca Montreal, Canada, December 14, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company specializing in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that it has emerged from its Court-supervised restructuring on December 11, 2009.

All transactions in connection with the implementation of the proposal filed by ART under the Bankruptcy and Insolvency Act (Canada) ("BIA") (the "Proposal") and the reorganization of ART's equity pursuant to Section 191 of the Canada Business Corporation Act (the "Reorganization") included therein have been completed.

ART's President, Sébastien Gignac, stated: "With Dorsky Worldwide Corp.'s critical support and the closing of the Proposal, ART is able to emerge from this restructuring process with the perspective of pursuing within a new group its operations and maintaining its highly-skilled and dedicated workforce as well as supporting its valuable clients. We wish to extend our deepest gratitude to our suppliers, service providers and distributors, for the strong support which they have given us throughout this difficult process. We intend to pursue the growth of our relationship with them to build a bright future together. It is regretful that our shareholders who have shared ART's history for many years until the very end have not realized value and have been disappointed by their investment in the ART. They have nonetheless participated in the development of a unique imaging platform and of two great molecular imaging products, SoftScan® and Optix®, whose true value will be to improve people's lives, especially women's, and get new and better drugs to market quicker. ART's challenging restructuring enables the survival of a reliable and state of the art technology emanating from Québec, Canada, in particular in the areas of cancer diagnostic and treatment monitoring, which are generating growing debates and high expectations unmet by conventional modalities", concluded Mr. Gignac.

ART obtained creditors approval of the Proposal on December 7, 2009 and a final order of the Quebec Superior Court of Justice (the "Court") under the BIA on December 9, 2009. Pursuant to the Proposal, Dorsky Worldwide Corp. ("Dorsky") has settled the claims of secured creditors of ART totaling close to $5 million and funded a distribution of $375,000 to be made by the Court-appointed trustee to the unsecured creditors of ART.  Dorsky is now ART's sole shareholder.

All existing common and preferred shares and other equity of ART outstanding prior to the implementation of the Proposal have been automatically cancelled, without payment or compensation to the holders of such shares and equity, in accordance with the terms of the Court approved Proposal. All warrants, rights, options, agreements and instruments to purchase shares of ART existing prior to the Proposal implementation are of no further force or effect, in accordance with the terms of the Court approved Proposal.

The common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of ART were de-listed from the Toronto Stock Exchange ("TSX") at the close of business on December 11, 2009. ART will apply to cease to be a reporting issuer in all applicable Provinces and territories of Canada.

About ART

ART Advanced Research Technologies Inc. develops and commercializes molecular imaging products for the healthcare and pharmaceutical industries. In accordance with TSX Bulletin No.2 009-1426 dated November 3, 2009, the TSX determined on November 12, 2009 to delist the common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of the Company (collectively, the "Securities") at the close of market on December 11, 2009 for failure to meet the continued listing requirements of TSX. For more information on ART and its restructuring, visit our website at www.art.ca.

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Sébastien Gignac:  sgignac@art.ca
President and Chief Executive Officer
Tel.  514.832.0777
Jacques Bédard:  jbedard@art.ca
Chief Financial Officer
Tel.  514.832.0777
www.art.ca

]]> ART Announces Completion of Restructuring Process with Implementation of Its Proposal Filed Under the Bankruptcy and Insolvency Act 2009-12-14 08:21:50 ART Announces Court Approval of Its Proposal Filed Under the Bankruptcy and Insolvency Act http://www.art.ca/en/news-events/press-release-art-announces-court-approval-its-544.php?y=2009 Montreal, Canada, December 9, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company specializing in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that the Quebec Superior Court approved today the amended proposal (the "Proposal") filed by ART under the Bankruptcy and Insolvency Act (Canada) (the "BIA"). The Proposal provides for, amongst other terms, the distribution of the sum of $375 000 to the unsecured creditors as well as a reorganization of ART's equity pursuant to Section 191 of the Canada Business Corporations Act (the "Reorganization"). The transactions contemplated by the Proposal including the Reorganization are expected to be implemented and effective by December 11, 2009.In consideration of the transactions contemplated under the Proposal, Dorsky Worldwide Corp. ("Dorsky") settled the claims of secured creditors of ART totaling close to $5 million and paid $375,000 to be used by ART to pay a distribution to its unsecured creditors. Upon the implementation of the Proposal and Reorganization, all existing common and preferred shares and other equity of ART will be automatically cancelled, without payment or compensation to the holders of such shares and equity, in accordance with the terms of the Court approved Proposal. This announcement follows the announcement made on December 7, 2009 that the unsecured creditors of ART (the "Unsecured Creditors") voted unanimously in support of its Proposal under the BIA, as amended, at a meeting of Unsecured Creditors held that day.About ART ART Advanced Research Technologies Inc. develops and commercializes molecular imaging products for the healthcare and pharmaceutical industries. In accordance with TSX Bulletin No.2 009-1426 dated November 3, 2009, the Toronto Stock Exchange ("TSX") determined on November 12, 2009 to delist the common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of the Company (collectively, the "Securities") at the close of market on December 11, 2009 for failure to meet the continued listing requirements of TSX. The Securities will remain suspended from trading. For more information on ART and its restructuring, visit our website at www.art.ca.-30-FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Jacques Bédard: jbedard@art.ca Chief Financial OfficerTel. 514.832.0777 Montreal, Canada, December 9, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company specializing in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that the Quebec Superior Court approved today the amended proposal (the "Proposal") filed by ART under the Bankruptcy and Insolvency Act (Canada) (the "BIA"). The Proposal provides for, amongst other terms, the distribution of the sum of $375 000 to the unsecured creditors as well as a reorganization of ART's equity pursuant to Section 191 of the Canada Business Corporations Act (the "Reorganization").

The transactions contemplated by the Proposal including the Reorganization are expected to be implemented and effective by December 11, 2009.

In consideration of the transactions contemplated under the Proposal, Dorsky Worldwide Corp. ("Dorsky") settled the claims of secured creditors of ART totaling close to $5 million and paid $375,000 to be used by ART to pay a distribution to its unsecured creditors.

Upon the implementation of the Proposal and Reorganization, all existing common and preferred shares and other equity of ART will be automatically cancelled, without payment or compensation to the holders of such shares and equity, in accordance with the terms of the Court approved Proposal. This announcement follows the announcement made on December 7, 2009 that the unsecured creditors of ART (the "Unsecured Creditors") voted unanimously in support of its Proposal under the BIA, as amended, at a meeting of Unsecured Creditors held that day.

About ART

ART Advanced Research Technologies Inc. develops and commercializes molecular imaging products for the healthcare and pharmaceutical industries. In accordance with TSX Bulletin No.2 009-1426 dated November 3, 2009, the Toronto Stock Exchange ("TSX") determined on November 12, 2009 to delist the common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of the Company (collectively, the "Securities") at the close of market on December 11, 2009 for failure to meet the continued listing requirements of TSX. The Securities will remain suspended from trading. For more information on ART and its restructuring, visit our website at www.art.ca.

-30-

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Announces Court Approval of Its Proposal Filed Under the Bankruptcy and Insolvency Act 2009-12-09 00:00:00 ART Announces Unanimous Support in Favour of Its Proposal to Creditors http://www.art.ca/en/news-events/press-release-art-announces-unanimous-support-favour-542.php?y=2009 Montreal, Canada, December 7, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that its unsecured creditors (the "Unsecured Creditors") voted unanimously in support of its proposal (the "Proposal") under the Bankruptcy and Insolvency Act (the "BIA"), as amended, at a meeting of Unsecured Creditors held today (the "Meeting"). Following the filing of an amended Proposal at the Meeting, the terms of which do not affect the distribution of the $375,000 available to ART's Unsecured Creditors, the Unsecured Creditors of ART voted in favor of the amended Proposal, with 100% of the votes cast supporting the Proposal.ART is scheduled to seek court approval of the amended Proposal on December 9, 2009.This announcement follows the announcement made on November 20, 2009 that ART entered on that day into an agreement today with Dorsky Worldwide Corp. to restructure ART's balance sheet and share capital and position it to continue in business. As contemplated in that agreement, ART filed on November 23, 2009 its Proposal to its Unsecured Creditors under the BIA through KPMG Inc. About ART ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.-30-FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Jacques Bédard: jbedard@art.ca Chief Financial OfficerTel. 514.832.0777 Montreal, Canada, December 7, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that its unsecured creditors (the "Unsecured Creditors") voted unanimously in support of its proposal (the "Proposal") under the Bankruptcy and Insolvency Act (the "BIA"), as amended, at a meeting of Unsecured Creditors held today (the "Meeting").

Following the filing of an amended Proposal at the Meeting, the terms of which do not affect the distribution of the $375,000 available to ART's Unsecured Creditors, the Unsecured Creditors of ART voted in favor of the amended Proposal, with 100% of the votes cast supporting the Proposal.

ART is scheduled to seek court approval of the amended Proposal on December 9, 2009.

This announcement follows the announcement made on November 20, 2009 that ART entered on that day into an agreement today with Dorsky Worldwide Corp. to restructure ART's balance sheet and share capital and position it to continue in business. As contemplated in that agreement, ART filed on November 23, 2009 its Proposal to its Unsecured Creditors under the BIA through KPMG Inc.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

-30-

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Announces Unanimous Support in Favour of Its Proposal to Creditors 2009-12-07 00:00:00 ART Announces Restructuring Agreement and Proposal to Creditors http://www.art.ca/en/news-events/press-release-art-announces-restructuring-agreement-proposal-540.php?y=2009 Montreal, Canada, November 20, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that its strategic review process has culminated in ART entering into an agreement today with Dorsky Worldwide Corp. ("Dorsky") to restructure ART's balance sheet and share capital and position it to continue in business. The agreement contemplates that ART will file a proposal (the "Proposal") to its unsecured creditors (the "Unsecured Creditors") under the Bankruptcy and Insolvency Act ("BIA") through KPMG Inc. (the "Trustee"). The meeting at which the Unsecured Creditors will vote on the Proposal is expected to be held on December 7, 2009 (the "Meeting"). The Proposal will provide, among other things, for the distribution of $375,000 to ART's Unsecured Creditors.The Proposal will also provide for the repayment of certain claims of secured creditors of ART, for the cancellation of all existing issued and outstanding equity in the capital of ART, including any and all issued and outstanding common or preferred shares of ART of every classes and series, and any and all warrants, options and any agreement to purchase any of the foregoing, and for the issuance of a new class of voting common shares of ART, representing 100% of the new voting common shares of ART, in favour of Dorsky. Holders of the existing equity of ART will not receive any payment or other compensation with respect to such equity.These announcements follow the announcement made on November 2, 2009 that ART filed on that day a notice of intention to make a proposal under the BIA. As authorized pursuant to an order of the Quebec Superior Court, ART also entered into a loan agreement with Dorsky for an interim financing of up to $1,200,000. The interim financing was put in place to support ART's ongoing operations by providing additional short-term liquidity to the company while allowing KPMG LLP and ART to pursue the strategic review process and continue soliciting purchase offers for the business and assets of ART.Moreover, ART was also informed today that the Autorité des marchés financiers issued a cease trade order (the "Cease Trade Order") against ART on November 19, 2009 since ART has not filed interim financial statements and interim management's discussion and analysis as prescribed by National Instrument 51-102 - Continuous Disclosure Obligations for the period ending September 30, 2009 within the time required. The Cease Trade Order requires ART, its securityholders and any other person to cease any activity in respect of a transaction in securities of ART. About ART ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Jacques Bédard: jbedard@art.ca Chief Financial OfficerTel. 514.832.0777 Montreal, Canada, November 20, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that its strategic review process has culminated in ART entering into an agreement today with Dorsky Worldwide Corp. ("Dorsky") to restructure ART's balance sheet and share capital and position it to continue in business.

The agreement contemplates that ART will file a proposal (the "Proposal") to its unsecured creditors (the "Unsecured Creditors") under the Bankruptcy and Insolvency Act ("BIA") through KPMG Inc. (the "Trustee"). The meeting at which the Unsecured Creditors will vote on the Proposal is expected to be held on December 7, 2009 (the "Meeting"). The Proposal will provide, among other things, for the distribution of $375,000 to ART's Unsecured Creditors.

The Proposal will also provide for the repayment of certain claims of secured creditors of ART, for the cancellation of all existing issued and outstanding equity in the capital of ART, including any and all issued and outstanding common or preferred shares of ART of every classes and series, and any and all warrants, options and any agreement to purchase any of the foregoing, and for the issuance of a new class of voting common shares of ART, representing 100% of the new voting common shares of ART, in favour of Dorsky. Holders of the existing equity of ART will not receive any payment or other compensation with respect to such equity.

These announcements follow the announcement made on November 2, 2009 that ART filed on that day a notice of intention to make a proposal under the BIA. As authorized pursuant to an order of the Quebec Superior Court, ART also entered into a loan agreement with Dorsky for an interim financing of up to $1,200,000. The interim financing was put in place to support ART's ongoing operations by providing additional short-term liquidity to the company while allowing KPMG LLP and ART to pursue the strategic review process and continue soliciting purchase offers for the business and assets of ART.

Moreover, ART was also informed today that the Autorité des marchés financiers issued a cease trade order (the "Cease Trade Order") against ART on November 19, 2009 since ART has not filed interim financial statements and interim management's discussion and analysis as prescribed by National Instrument 51-102 - Continuous Disclosure Obligations for the period ending September 30, 2009 within the time required. The Cease Trade Order requires ART, its securityholders and any other person to cease any activity in respect of a transaction in securities of ART.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Announces Restructuring Agreement and Proposal to Creditors 2009-11-20 00:00:00 ART Announces Delay in the Release of Its Third Quarter Results and Receipt of Notice of Delisting From TSX Effective December 11, 2009 http://www.art.ca/en/news-events/press-release-art-announces-delay-release-its-538.php?y=2009 Montreal, Canada, November 13, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that it will delay the release of its financial results for the third quarter ended September 30, 2009, considering the restructuring process that the company is currently undergoing. As announced on November 2, 2009, ART filed on that day a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act through KPMG Inc. ART was also authorized pursuant to an order of the Quebec Superior Court to enter into a loan agreement with Dorsky Worldwide Corp. for an interim financing of up to $1,200,000. On October 29, 2009, ART had announced the appointment of KPMG LLP as financial advisor to assist ART in examining its available strategic options in view of the company's ongoing financial needs. The interim financing was put in place to support ART's ongoing operations by providing additional short-term liquidity to the company while allowing KPMG LLP and ART to pursue the strategic review process and continue soliciting purchase offers for the business and assets of ART.Considering the process that the company is currently undergoing, there can be no assurance that the current initiatives undertaken by KPMG LLP and ART will be successful. In light of the uncertainties related to the company's ability to continue as a going concern, the interim financial statements could require material adjustments to the carrying value and classification of assets and liabilities and reported results of operations. Such adjustments could be material. Therefore, the company has decided to delay the release of its third quarter results until such time as the company will have some reasonable assurance as to the outcome of these initiatives.ART also announced today that it has received a letter from The Toronto Stock Exchange ("TSX") indicating that the Continued Listings Committee of the TSX has determined to delist the common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of the company (collectively, the "Securities") effective at the close of market on December 11, 2009. The delisting was imposed for failure by ART to meet the continued listing requirements of the TSX, as detailed in Part VII of The TSX Company Manual. Trading in ART's Securities will remain suspended.About ART ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.-30-For more information, please contact:ART Advanced Research Technologies Inc.Jacques BedardChief Financial Officer514-832-0777jbedard@art.ca Montreal, Canada, November 13, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that it will delay the release of its financial results for the third quarter ended September 30, 2009, considering the restructuring process that the company is currently undergoing.

As announced on November 2, 2009, ART filed on that day a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act through KPMG Inc. ART was also authorized pursuant to an order of the Quebec Superior Court to enter into a loan agreement with Dorsky Worldwide Corp. for an interim financing of up to $1,200,000.

On October 29, 2009, ART had announced the appointment of KPMG LLP as financial advisor to assist ART in examining its available strategic options in view of the company's ongoing financial needs. The interim financing was put in place to support ART's ongoing operations by providing additional short-term liquidity to the company while allowing KPMG LLP and ART to pursue the strategic review process and continue soliciting purchase offers for the business and assets of ART.

Considering the process that the company is currently undergoing, there can be no assurance that the current initiatives undertaken by KPMG LLP and ART will be successful. In light of the uncertainties related to the company's ability to continue as a going concern, the interim financial statements could require material adjustments to the carrying value and classification of assets and liabilities and reported results of operations. Such adjustments could be material. Therefore, the company has decided to delay the release of its third quarter results until such time as the company will have some reasonable assurance as to the outcome of these initiatives.

ART also announced today that it has received a letter from The Toronto Stock Exchange ("TSX") indicating that the Continued Listings Committee of the TSX has determined to delist the common shares (Symbol: ARA), the Series 1 Preferred Shares (Symbol: ARA.PR.A) and the Series 2 Preferred Shares (Symbol: ARA.PR.B) of the company (collectively, the "Securities") effective at the close of market on December 11, 2009. The delisting was imposed for failure by ART to meet the continued listing requirements of the TSX, as detailed in Part VII of The TSX Company Manual. Trading in ART's Securities will remain suspended.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

-30-

For more information, please contact:

ART Advanced Research Technologies Inc.
Jacques Bedard
Chief Financial Officer
514-832-0777
jbedard@art.ca

]]> ART Announces Delay in the Release of Its Third Quarter Results and Receipt of Notice of Delisting From TSX Effective December 11, 2009 2009-11-13 00:00:00 ART Secures up to $1.2 Million in Interim Financing in Connection with the Pursuit of its Strategic Review Process and Files a Notice of Intention Under the Bankruptcy and Insolvency Act http://www.art.ca/en/news-events/press-release-art-secures-up-1-2-536.php?y=2009 Montreal, Canada, November 2, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced that earlier today it filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act with KPMG Inc. in order to provide the company with the liquidity it requires to pursue its solicitation process. ART was also authorized pursuant to an order of the Quebec Superior Court to enter into a loan agreement with Dorsky Worldwide Corp. for interim financing in an amount of up to $1,200,000. The announcement follows the hiring of KPMG LLP as financial advisor to assist ART in examining its available strategic options, previously announced on October 29, 2009, and KPMG LLP's analysis as to the best way to proceed during the strategic review process in view of ART's ongoing financial needs. The new financing will support ART's business continuity by providing additional short-term liquidity while KPMG LLP and ART pursue the strategic review process and continue soliciting purchase offers for the business and assets of ART.About ARTART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Jacques Bédard: jbedard@art.caChief Financial OfficerTel. 514.832.0777 Montreal, Canada, November 2, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced that earlier today it filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act with KPMG Inc. in order to provide the company with the liquidity it requires to pursue its solicitation process. ART was also authorized pursuant to an order of the Quebec Superior Court to enter into a loan agreement with Dorsky Worldwide Corp. for interim financing in an amount of up to $1,200,000.

The announcement follows the hiring of KPMG LLP as financial advisor to assist ART in examining its available strategic options, previously announced on October 29, 2009, and KPMG LLP's analysis as to the best way to proceed during the strategic review process in view of ART's ongoing financial needs. The new financing will support ART's business continuity by providing additional short-term liquidity while KPMG LLP and ART pursue the strategic review process and continue soliciting purchase offers for the business and assets of ART.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Secures up to $1.2 Million in Interim Financing in Connection with the Pursuit of its Strategic Review Process and Files a Notice of Intention Under the Bankruptcy and Insolvency Act 2009-11-03 13:33:00 ART Announces Review of Strategic Options and Downsizing http://www.art.ca/en/news-events/press-release-art-announces-review-strategic-options-534.php?y=2009 Montreal, Canada, October 29, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that in view of the Company's ongoing financial needs, its Board of Directors has initiated a process to explore strategic options available to the Company. Concurrently with this strategic review, the Company has implemented a downsizing of its workforce. The Board has retained KPMG LLP as financial advisor to assist in examining strategic options available to the Company which may include a recapitalization of the Company, a sale of some or all of its assets, or a restructuring the Company's operations. As part of this strategic options review, the Board has authorized the Company to explore whether third parties would have interest in acquiring the Company.However, there can be no assurance that the review will result in any specific strategic or financial transactions. The Company does not plan to make future comments about the status of the review of strategic options unless there are material developments.In connection with its strategic options review, the Company has announced a downsizing affecting 35 employees, including 15 lay-offs, resignations or positions abolished, that will result in a 43 % reduction of its operating expenses.The Company's Chairman & CEO, Sébastien Gignac, stated: "In light of the challenges involved in securing additional financing in the current economic context, and after careful consideration, the Board of Directors has determined that the Company should undertake a process to explore its strategic options. The Board has also concluded that the Company must reorganize and eliminate certain positions in order to reduce our expenditures during this process."About ART ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.-30-FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Jacques Bédard: jbedard@art.ca Chief Financial OfficerTel. 514.832.0777 Montreal, Canada, October 29, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that in view of the Company's ongoing financial needs, its Board of Directors has initiated a process to explore strategic options available to the Company. Concurrently with this strategic review, the Company has implemented a downsizing of its workforce.

The Board has retained KPMG LLP as financial advisor to assist in examining strategic options available to the Company which may include a recapitalization of the Company, a sale of some or all of its assets, or a restructuring the Company's operations. As part of this strategic options review, the Board has authorized the Company to explore whether third parties would have interest in acquiring the Company.

However, there can be no assurance that the review will result in any specific strategic or financial transactions. The Company does not plan to make future comments about the status of the review of strategic options unless there are material developments.

In connection with its strategic options review, the Company has announced a downsizing affecting 35 employees, including 15 lay-offs, resignations or positions abolished, that will result in a 43 % reduction of its operating expenses.

The Company's Chairman & CEO, Sébastien Gignac, stated: "In light of the challenges involved in securing additional financing in the current economic context, and after careful consideration, the Board of Directors has determined that the Company should undertake a process to explore its strategic options. The Board has also concluded that the Company must reorganize and eliminate certain positions in order to reduce our expenditures during this process."

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

-30-

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Announces Review of Strategic Options and Downsizing 2009-10-29 09:40:00 ART Time Domain Technology Applications to be Presented at the World Molecular Imaging Congress in Montréal, Canada http://www.art.ca/en/news-events/press-release-art-time-domain-technology-applications-532.php?y=2009 Presentations highlight ongoing research for ART's Optix, SoftScan, and Fenestra products Montreal, Canada, September 24, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be featured in several scientific research presentations based on ART's SoftScan® optical imaging device, Optix® in vivo fluorescence optical imaging system, and Fenestra® imaging agent for microCT, at the World Molecular Imaging Congress (WMIC), being held at the Palais des congrès in Montréal, Canada, from September 23 to 26, 2009.Thursday, September 24, 2009 - 4:00 PM to 5:30 PMPoster Presentation Number: 1088. Quantitative in vivo 3D fluorescence lifetime imaging of a liver-specific agent. G. Ma; D. Huang; M. Piché; M. Jean-Jacques; S.Fortier; M. Khayat.Poster Presentation Number: 0300. Molecular imaging of pancreatic beta-cell mass: An antibody mediated optical imaging approach. D. Vats; F. Stuker; K. Dikaiou; H. Wang; H. Matile; C. Migliorini; M. Rudin.Poster Presentation Number: 1215. Multimodal Molecular Imaging of Brain Cancer Using Nanoparticles Functionalized with IGFBP7 Single Domain Antibody. H. Albaghdadi; U. Iqbal; R. Mackenzie; D. Celine; T. Veres; D. Stanimirovic; B. Blasiak; B. Tomanek; G. Sutherland; A. Abulrob.Poster Presentation Number: 1283. Exploring Novel Optical Imaging Methods for Quantifying Muscle Damage and Inflammation in Mouse Models of Muscular Dystrophy. A.R. Baudy; E. Hoffman; K. Nagaraju.Poster Presentation Number: 1030. Early Detection of Metastasis Tumors in Mouse Liver Model Using Gated Small Animal FDG PET and Contrast CT Images. S. Woo; G. Cheon; K. Kim; T. Lee; J. Jung; Y. Lee; J. Kang; J. Park; J. Kim; J. Kim; S. Lim.Poster Presentation Number: 0700. Liposome Contrast Agent for CT-based Detection andLocalization of Neoplastic and Inflammatory Lesions in Rabbits: Validation with FDG-PET and Histology. J. Zheng; C. Allen; D.C.Vines; S. Serra; M. Charron; D.A. Jaffray.Friday, September 25, 2009 - 4:00 PM to 5:30 PMPoster Presentation Number: 1119. Molecular Imaging using Nanotubes and a Clinical Optical Breast Imaging System. S.M. Van de Ven; N. Mincu; J. Brunette; G. Ma; M. Khayat; D.M. Ikeda; S.S. Gambhir.Poster Presentation Number: 1005. Micro-CT small animal imaging enhanced by Fenestra LC and meglumine diatrizoate. S. Zhu; J. Tian; X. Ma; X. Zhang; G. Yan.Poster Presentation Number: 1006. Negative Contrast Enhancement Enables Visualization ofIntraperitoneal Tumors in Mice Using CT. M. Rampurwala; M.K. Ravoori; W. Wei; V. Johnson; R. Vikram; V. Kundra.Saturday, September 26, 20091:00 PM to 2:30 PMOral Presentation Number: 0217. Quantitative Dynamic SPECT/CT Imaging of Atherosclerotic Plaques in ApoE-/- Mice. B.M. Tsui; J. Yu; Y. Wang; G.S. Mok; S. Nimmagadda; D. Bedja; K.L. Gabrielson; F. Bengel; M. Pomper.Oral Presentation Number: 0200. Replacing Vascular Corrosion Casting by in-vivo μCT Imaging for Building 3D Cardiovascular Models in Mice. B. Vandeghinste; B. Trachet; M. Renard; C. Casteleyn; S. Deleye; P. Joye; S. Vandenberghe; S.G. Staelens; P. Segers; B. Loeys.4:00 PM to 5:30 PM Poster Presentation Number: 0512. Whole-body fluorescence lifetime imaging of human melanoma metastases in mice using Green Fluorescence Protein (GFP). D. Huang; M. Piché; M. Jean-Jacques; G. Ma; M. Khayat.Poster Presentation Number: 0511. Early detection of human breast cancer MCF-7 using anti-EpCAM antibody conjugated with Cy5.5. D. Huang; M. Piché; M. Jean-Jacques; G. Ma; M. Khayat.Poster Presentation Number: 1268. Molecular Imaging of Brain Tumor Vessels Using Anti-IGFBP7 Single Domain Antibody Constructs. U. Iqbal; H. Albaghdadi; R. Mackenzie; B. Tomanek; G. Sutherland; D. Stanimirovic; A. Abulrob.Poster Presentation Number: 0962. Multimodal therapeutic monitoring of HSV1-tk/GCV gene therapy using I-124-FIAU-PET, bioluminescence and liver contrast enhance CT in orthotopic hepatoma model. T. Lee; S. Woo; J. Jung; K. Woo; W. Chung; J. Kang; Y. Lee; K. Kim; G. Cheon; S. Lim.Full texts of the abstracts can be obtained through the WMIC Itinerary Planner (http://wmicmeeting.org/dev/content/view/74/104/).About ART ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.-30-FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Dino DiCamillo: ddicamil@art.caVice President, Global Sales and Marketing, Preclinical ImagingJacques Bédard: jbedard@art.ca Chief Financial OfficerTel. 514.832.0777 Presentations highlight ongoing research for ART's Optix, SoftScan, and Fenestra products

Montreal, Canada, September 24, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be featured in several scientific research presentations based on ART's SoftScan® optical imaging device, Optix® in vivo fluorescence optical imaging system, and Fenestra® imaging agent for microCT, at the World Molecular Imaging Congress (WMIC), being held at the Palais des congrès in Montréal, Canada, from September 23 to 26, 2009.


Thursday, September 24, 2009 - 4:00 PM to 5:30 PM
Poster Presentation Number: 1088. Quantitative in vivo 3D fluorescence lifetime imaging of a liver-specific agent. G. Ma; D. Huang; M. Piché; M. Jean-Jacques; S.Fortier; M. Khayat.

Poster Presentation Number: 0300. Molecular imaging of pancreatic beta-cell mass: An antibody mediated optical imaging approach. D. Vats; F. Stuker; K. Dikaiou; H. Wang; H. Matile; C. Migliorini; M. Rudin.

Poster Presentation Number: 1215. Multimodal Molecular Imaging of Brain Cancer Using Nanoparticles Functionalized with IGFBP7 Single Domain Antibody. H. Albaghdadi; U. Iqbal; R. Mackenzie; D. Celine; T. Veres; D. Stanimirovic; B. Blasiak; B. Tomanek; G. Sutherland; A. Abulrob.

Poster Presentation Number: 1283. Exploring Novel Optical Imaging Methods for Quantifying Muscle Damage and Inflammation in Mouse Models of Muscular Dystrophy. A.R. Baudy; E. Hoffman; K. Nagaraju.

Poster Presentation Number: 1030. Early Detection of Metastasis Tumors in Mouse Liver Model Using Gated Small Animal FDG PET and Contrast CT Images. S. Woo; G. Cheon; K. Kim; T. Lee; J. Jung; Y. Lee; J. Kang; J. Park; J. Kim; J. Kim; S. Lim.

Poster Presentation Number: 0700. Liposome Contrast Agent for CT-based Detection and
Localization of Neoplastic and Inflammatory Lesions in Rabbits: Validation with FDG-PET and Histology. J. Zheng; C. Allen; D.C.Vines; S. Serra; M. Charron; D.A. Jaffray.


Friday, September 25, 2009 - 4:00 PM to 5:30 PM
Poster Presentation Number: 1119. Molecular Imaging using Nanotubes and a Clinical Optical Breast Imaging System. S.M. Van de Ven; N. Mincu; J. Brunette; G. Ma; M. Khayat; D.M. Ikeda; S.S. Gambhir.

Poster Presentation Number: 1005. Micro-CT small animal imaging enhanced by Fenestra LC and meglumine diatrizoate. S. Zhu; J. Tian; X. Ma; X. Zhang; G. Yan.

Poster Presentation Number: 1006. Negative Contrast Enhancement Enables Visualization of
Intraperitoneal Tumors in Mice Using CT. M. Rampurwala; M.K. Ravoori; W. Wei; V. Johnson; R. Vikram; V. Kundra.


Saturday, September 26, 2009
1:00 PM to 2:30 PM
Oral Presentation Number: 0217. Quantitative Dynamic SPECT/CT Imaging of Atherosclerotic Plaques in ApoE-/- Mice. B.M. Tsui; J. Yu; Y. Wang; G.S. Mok; S. Nimmagadda; D. Bedja; K.L. Gabrielson; F. Bengel; M. Pomper.

Oral Presentation Number: 0200. Replacing Vascular Corrosion Casting by in-vivo μCT Imaging for Building 3D Cardiovascular Models in Mice. B. Vandeghinste; B. Trachet; M. Renard; C. Casteleyn; S. Deleye; P. Joye; S. Vandenberghe; S.G. Staelens; P. Segers; B. Loeys.

4:00 PM to 5:30 PM
Poster Presentation Number: 0512. Whole-body fluorescence lifetime imaging of human melanoma metastases in mice using Green Fluorescence Protein (GFP). D. Huang; M. Piché; M. Jean-Jacques; G. Ma; M. Khayat.

Poster Presentation Number: 0511. Early detection of human breast cancer MCF-7 using anti-EpCAM antibody conjugated with Cy5.5. D. Huang; M. Piché; M. Jean-Jacques; G. Ma; M. Khayat.

Poster Presentation Number: 1268. Molecular Imaging of Brain Tumor Vessels Using Anti-IGFBP7 Single Domain Antibody Constructs. U. Iqbal; H. Albaghdadi; R. Mackenzie; B. Tomanek; G. Sutherland; D. Stanimirovic; A. Abulrob.

Poster Presentation Number: 0962. Multimodal therapeutic monitoring of HSV1-tk/GCV gene therapy using I-124-FIAU-PET, bioluminescence and liver contrast enhance CT in orthotopic hepatoma model. T. Lee; S. Woo; J. Jung; K. Woo; W. Chung; J. Kang; Y. Lee; K. Kim; G. Cheon; S. Lim.

Full texts of the abstracts can be obtained through the WMIC Itinerary Planner (http://wmicmeeting.org/dev/content/view/74/104/).


About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

-30-

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Dino DiCamillo: ddicamil@art.ca
Vice President, Global Sales and Marketing, Preclinical Imaging

Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Time Domain Technology Applications to be Presented at the World Molecular Imaging Congress in Montréal, Canada 2009-09-24 10:19:54 ART Launches Optix MX3 Molecular Imaging System at WMIC2009 http://www.art.ca/en/news-events/press-release-art-launches-optix-mx3-molecular-530.php?y=2009 Optix MX3 offers a new benchmark for imaging performance and versatility in the preclinical phases of drug development Montreal, Canada, September 23, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress. The event is being held this year in Montreal, Canada, from September 23 to 26. ART is also featuring the Optix® MX3, as well as its SoftScan® and Fenestra® product offering, as an exhibitor at the event (booth #301), in the Exhibit Hall of the Palais des congrès de Montréal. "The Optix MX3 addresses a real market need as customers in the drug discovery and development process continue to demand tools providing an extensive qualitative and quantitative data set in small animal research, while ensuring reliability and performance for applications requiring longitudinal studies," said Sébastien Gignac, Chairman & CEO of ART. "While products currently on the market can only detect the intensity of the signal coming from a mouse specimen, the Optix MX3 system quite effectively exploits the power of our time domain technology to move beyond this type of signal measurement to obtain much richer and complex data. Indeed, with our Optix MX3, scientists are actually able to gain confidence in the exactitude of their results, by accurately differentiating various compound types and determining their concentration and depth precisely.""We are excited to announce that the Optix MX3 is now available through our dedicated sales teams in North America and Europe, as well as our regional distribution partners in Italy, India, Japan, Korea and the United Kingdom," said Dino DiCamillo, Vice President, Global Sales & Marketing, of ART.The compact Optix MX3 system offers the highest sensitivity among fluorescent systems in the preclinical market and unique optical molecular imaging features. The completely re-engineered and redesigned Optix platform will mean an increase in performance level, entail savings in manufacturing costs, and will incorporate new technological market drivers, such as the ability to image red fluorescent proteins, Q-dots, and the complete spectrum ranging from 450 nm to 850 nm with the support of a state-of-the-art tunable laser. Using ART's proven and proprietary time-domain technology, which allows measurement of the light's time of arrival, Optix MX3 is sensitive enough to detect target signals deep within the organs of small animals. Unique to the Optix MX3 is the ability to recover fluorescence lifetime, which can be used to separate and quantify fluorescent probe distributions depending on their respective biochemical environment. Also part of the Optix MX3 is the CT fusion software package allowing researchers to export the scan obtained using Optix MX3 in DICOM format, and fuse it with micro-CT for a full 3D anatomical reference.About ART ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Dino DiCamillo: ddicamil@art.caVice President, Global Sales and Marketing, Preclinical ImagingJacques Bédard: jbedard@art.ca Chief Financial OfficerTel. 514.832.0777 Optix MX3 offers a new benchmark for imaging performance and versatility in the preclinical phases of drug development


Montreal, Canada, September 23, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress. The event is being held this year in Montreal, Canada, from September 23 to 26. ART is also featuring the Optix® MX3, as well as its SoftScan® and Fenestra® product offering, as an exhibitor at the event (booth #301), in the Exhibit Hall of the Palais des congrès de Montréal.

"The Optix MX3 addresses a real market need as customers in the drug discovery and development process continue to demand tools providing an extensive qualitative and quantitative data set in small animal research, while ensuring reliability and performance for applications requiring longitudinal studies," said Sébastien Gignac, Chairman & CEO of ART. "While products currently on the market can only detect the intensity of the signal coming from a mouse specimen, the Optix MX3 system quite effectively exploits the power of our time domain technology to move beyond this type of signal measurement to obtain much richer and complex data. Indeed, with our Optix MX3, scientists are actually able to gain confidence in the exactitude of their results, by accurately differentiating various compound types and determining their concentration and depth precisely."

"We are excited to announce that the Optix MX3 is now available through our dedicated sales teams in North America and Europe, as well as our regional distribution partners in Italy, India, Japan, Korea and the United Kingdom," said Dino DiCamillo, Vice President, Global Sales & Marketing, of ART.

The compact Optix MX3 system offers the highest sensitivity among fluorescent systems in the preclinical market and unique optical molecular imaging features. The completely re-engineered and redesigned Optix platform will mean an increase in performance level, entail savings in manufacturing costs, and will incorporate new technological market drivers, such as the ability to image red fluorescent proteins, Q-dots, and the complete spectrum ranging from 450 nm to 850 nm with the support of a state-of-the-art tunable laser.

Using ART's proven and proprietary time-domain technology, which allows measurement of the light's time of arrival, Optix MX3 is sensitive enough to detect target signals deep within the organs of small animals. Unique to the Optix MX3 is the ability to recover fluorescence lifetime, which can be used to separate and quantify fluorescent probe distributions depending on their respective biochemical environment. Also part of the Optix MX3 is the CT fusion software package allowing researchers to export the scan obtained using Optix MX3 in DICOM format, and fuse it with micro-CT for a full 3D anatomical reference.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Dino DiCamillo: ddicamil@art.ca
Vice President, Global Sales and Marketing, Preclinical Imaging

Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Launches Optix MX3 Molecular Imaging System at WMIC2009 2009-09-23 09:53:21 ART Translational Imaging Platform Showcased at the World Molecular Imaging Congress in Montreal, Canada http://www.art.ca/en/news-events/press-release-art-translational-imaging-platform-showcased-528.php?y=2009 Montreal, Canada, September 21, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that current research relating to its molecular imaging products will be presented at poster sessions at the World Molecular Imaging Congress (WMIC), being held at the Palais des congrès in Montreal, Canada, from September 23 to 26, 2009. ART is also displaying its Optix®, SoftScan® and Fenestra® product offering as an exhibitor at the event (booth #301), in the Exhibit Hall of the Palais des congrès.Prior to the start of the meeting - on Tuesday, September 22 - ART will hold a ART User Forum, where Optix users from major pharmaceutical companies and research institutes will present their work, and provide a hands-on opportunity for potential clients to learn about new developments and applications available for the Optix system, as well as the capability for translational research using the SoftScan® breast imaging device. Both products are based on the proprietary time domain technology developed by ART, which allows for more accurate recovery of depth and concentration than other optical systems. About ART ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.-30-FOR FURTHER INFORMATION, PLEASE CONTACT:ART Advanced Research Technologies Inc.Dino DiCamillo: ddicamil@art.caVice President, Global Sales and Marketing, Preclinical ImagingJacques Bédard: jbedard@art.ca Chief Financial OfficerTel. 514.832.0777 Montreal, Canada, September 21, 2009 - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that current research relating to its molecular imaging products will be presented at poster sessions at the World Molecular Imaging Congress (WMIC), being held at the Palais des congrès in Montreal, Canada, from September 23 to 26, 2009. ART is also displaying its Optix®, SoftScan® and Fenestra® product offering as an exhibitor at the event (booth #301), in the Exhibit Hall of the Palais des congrès.

Prior to the start of the meeting - on Tuesday, September 22 - ART will hold a ART User Forum, where Optix users from major pharmaceutical companies and research institutes will present their work, and provide a hands-on opportunity for potential clients to learn about new developments and applications available for the Optix system, as well as the capability for translational research using the SoftScan® breast imaging device. Both products are based on the proprietary time domain technology developed by ART, which allows for more accurate recovery of depth and concentration than other optical systems.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities.

-30-

FOR FURTHER INFORMATION, PLEASE CONTACT:

ART Advanced Research Technologies Inc.
Dino DiCamillo: ddicamil@art.ca
Vice President, Global Sales and Marketing, Preclinical Imaging

Jacques Bédard: jbedard@art.ca
Chief Financial Officer
Tel. 514.832.0777

]]> ART Translational Imaging Platform Showcased at the World Molecular Imaging Congress in Montreal, Canada 2009-09-21 10:04:09